Immunocore Holdings PLC (IMCR)
32.12
-0.30
(-0.93%)
USD |
NASDAQ |
Nov 21, 16:00
32.06
-0.06
(-0.19%)
After-Hours: 20:00
Immunocore Holdings Revenue (Quarterly): 80.25M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 80.25M |
| June 30, 2024 | 75.40M |
| March 31, 2024 | 70.50M |
| December 31, 2023 | 70.16M |
| September 30, 2023 | 64.85M |
| June 30, 2023 | 59.76M |
| March 31, 2023 | 54.66M |
| December 31, 2022 | 67.52M |
| September 30, 2022 | 46.01M |
| June 30, 2022 | 38.81M |
| Date | Value |
|---|---|
| March 31, 2022 | 29.52M |
| December 31, 2021 | 9.728M |
| September 30, 2021 | 7.954M |
| June 30, 2021 | 7.934M |
| March 31, 2021 | 11.37M |
| December 31, 2020 | 11.85M |
| September 30, 2020 | 8.557M |
| June 30, 2020 | 9.585M |
| March 31, 2020 | 10.21M |
| December 31, 2019 | 9.039M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.934M
Minimum
Jun 2021
80.25M
Maximum
Sep 2024
37.18M
Average
34.17M
Median
Revenue (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 40.90M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 5.624M |
| NuCana PLC | -- |
| Autolus Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 8.736M |
| Total Expenses (Quarterly) | 88.75M |
| EPS Diluted (Quarterly) | 0.17 |
| Enterprise Value | 1.159B |
| Gross Profit Margin (Quarterly) | 99.44% |
| Profit Margin (Quarterly) | 10.89% |
| Earnings Yield | -2.96% |
| Normalized Earnings Yield | -2.395 |